Position in BHVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$26,485,685
-$12,695,256 QoQ
Shares Held
1,779,952
-61.6% QoQ
Ownership
1.18%
of shares outstanding
% of Portfolio
0.64%
of 13F equity value
Holder Rank
#18
of 294 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BHVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TCG Crossover Management, LLC holds $3,891,479,135 across 48 Biotechnology names. BHVN ranks #35 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
6,007,834 | $800,603,958 | |
| 2 | TNGX |
Tango Therapeutics, Inc.
|
9,081,201 | $283,878,343 | |
| 3 | CGON |
CG Oncology, Inc.
|
3,670,206 | $260,768,136 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
4,854,436 | $187,866,673 | |
| 5 | IMVT |
Immunovant, Inc.
|
4,457,988 | $171,766,277 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,900,582 | $168,733,669 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,676,624 | $163,437,307 | |
| 8 | MIRM |
Mirum Pharmaceuticals, Inc.
|
1,062,049 | $124,334,076 |
All Filings in BHVN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $26,485,685 | 1,779,952 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $39,180,941 | 4,631,317 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $52,287,568 | 4,631,317 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||